AstraZeneca's chief executive, Pascal Soriot, has built a proven winning strategy based on smart licensing and partnerships, making a potential $400bn (£300bn) mega-merger with US group Bristol Myers Squibb (BMS) look baffling and high-risk. The Anglo-Swedish drugmaker's shares fell nearly 9% on Monday as investors struggled to see the logic in such a deal, which could jeopardize Soriot's legacy if it goes wrong.
Why the BMS Merger Makes Little Sense
The flirtation with a grand combination with BMS is puzzling, especially given Soriot's track record. His tenure has been a triumph, starting with the against-the-odds victory over Pfizer in 2014. The $39bn (£29bn) purchase of Alexion in 2021, though slightly over-priced, aligned with his emphasis on backing science and opened doors to rare diseases, promising decades of growth.
In contrast, a BMS merger would require ripping out billions in costs to justify the takeover premium, a move Soriot has typically viewed as anti-patient. Moreover, the timing is unclear, and the company has not even confirmed the basic accuracy of the initial report, suggesting talks could be quietly ditched. One hopes that will be the outcome, as the 67-year-old risks spoiling his legacy if a high-risk financial adventure fails.
Financial Risks and Patent Cliff
Acquiring a $133bn (£99bn) rival would inevitably bring a large debt burden. As Jefferies' analyst commented, "If there is one company that doesn't need financial engineering it's AZ in our view." The only guarantee is that AZ would inherit BMS's patent cliff, with sales of its blockbuster cancer treatment Opdivo plunging by 2030. While BMS might seek shelter, it's hard to see why AZ would pay for the umbrella.
The theoretical appeal might be building a market-beating oncology colossus, but Soriot's strategy of supplementing AZ's own development drugs with smart licensing and partnerships, especially in China, is already a proven winner. Why mess with the formula? US regulators might also object to two leading oncology franchises merging, leading to a long, distracting approval process.
Plan A: Simplicity and Confidence
Plan A has the virtue of simplicity. Just last week, Soriot expressed "absolute confidence" in hitting AZ's 2030 target of $80bn in annual revenues, despite a heart disease drug failure in late-stage trials. He highlighted that investors should see the drug business as involving hiccups, but put this blemish in context of the "20 high-value readouts due over the next 18 months."
The background worry is that Soriot's enthusiasm for US risk-taking might lead to the conclusion that AZ needs to join the pharmaceutical establishment in the US, despite already investing $50bn in US R&D and manufacturing. Last autumn, AZ "harmonised" its listing on the New York Stock Exchange, which could simplify US deal-making, but not all US deals are alike.
Market Reaction and Legacy
The thumping near-9% fall in AZ's share price on Monday spoke volumes: shareholders of all stripes struggled to see the sense in a mega-deal with BMS. Viewed through patriotic British eyes, one can worry about AZ's transatlantic drift or applaud the sight of a UK-based company in the driver's seat. Either way, the commercial logic must add up.
This idea looks wholly out of character for AZ. It is best dropped. Soriot's proven formula of smart licensing and partnerships, coupled with internal R&D, has delivered success without the need for a risky mega-merger.
